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CA   contrast agent 
CMR   cardiovascular magnetic resonance 
DE MRI  delayed enhancement MRI 
DSMRI  dobutamine stress MRI 
FOV   field of view 
Gd(ABE-DTTA) gadolinium (N-(2-butyryloxyethyl)-N¢-(2-ethyloxyethyl)-N,N¢-
bis[N¢¢,N¢¢-bis(carboxymethyl)acetamido]-1,2-ethanediamine 
Gd(DTPA)  gadolinium diethlynetriamine penta-acetic acid 
IR   inversion recovery 
LAD   left anterior descending coronary artery 
LE MRI  late enhancement MRI 
MRI   magnetic resonance imaging 
R1   longitudinal relaxation rate 
ROI   region of interest 
SI   signal intensity 
SIE   signal intensity enhancement 
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T1   longitudinal relaxation time 
T2   transverse relaxation time 



















1.1 Ischemic Heart Disease and Development of Diagnostic Imaging 
Ischemic heart disease remains the leading cause of death in the Western world, and myocardial 
infarction is a key component of the burden of cardiovascular disease [1]. Efforts for the 
decrease of the incidence and case fatality of myocardial infarction are important determinants of 
the desired decline in coronary disease mortality. One of the key elements of these efforts could 
be the better recognition of pathological processes of different tissues following myocardial 
infarct. Medical, surgical or interventional treatment needs to be tailored for each individual 
patient based on the ongoing pathological processes. This requires accurate and quantitative 
assessment of the underlying pathology. The development of different imaging modalities could 
lead to better in vivo assessment of the irreversibly injured myocardial tissue as well as of the 
ongoing pathological processes during the healing of myocardial scar following myocardial 
infarct. This may contribute to the progress in the research field of scar tissue evolution process. 
The progress of this research area may supply the intervention to the scar tissue evolution 
processes, which could lead to better quality of treatment and better outcome for patients 
following myocardial infarct.  
Another important aspect for the decline of the mortality of cardiovascular disease could be the 
identification of patients without symptoms but having the highest risk for cardiovascular 
mortality. Peripheral arterial disease (PAD) is a significant epidemiological problem by which 
60.000 percutane angioplasty (PTA) and 100.000 amputations are implemented annually in the 
USA [2]. Due to the systemic nature of the atherosclerosis and because of the typical existence 
of multiplex lesions, patients with peripheral arterial disease often have coronary heart disease, 
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as well. Therefore, the risk of coronary events is high. Most of the patients with PAD dies in 
consequence of his/her coronary artery disease [3]. Also very serious coronary artery disease can 
remain often asymptomatic because of the physical disability of the patient with PAD. The 
cardiology assessment of patients with PAD would be of great importance even if they do not 
have cardiac symptoms. Medical, surgical or interventional treatment for each identified patient 
being at high risk for undesirable cardiovascular events is warranted to decrease coronary disease 
mortality in this subgroup of patients. 
 
1.2 MRI – Imaging Modality for in Vivo Assessment of Tissue Pathology 
Magnetic Resonance Imaging (MRI) is a unique, high resolution, noninvasive imaging technique 
which came into clinical use in the early 1980s. Unlike x-rays, radioisotope studies, and even 
computed tomography (CT) studies, it does not rely on radiation. Instead, it is based on the 
principles of nuclear magnetic resonance (NMR) spectroscopy. Images are generated by spatially 
encoding the NMR signal coming from nuclei (eg. protons) present in the object [4]. The NMR 
signals are induced by the application of time-varying linear magnetic field gradients [5]. In the 
course of the most commonly used 1H MRI, radio waves are directed at protons, the nuclei of 
hydrogen atoms, in a strong magnetic field. The protons are first “excited” and then “relaxed”, 
causing them to emit radio signals that can be processed by computer to form an image.  In the 
body, protons are most abundant in hydrogen atoms of water. 1H MRI shows differences in the 
water content and distribution in various body tissues, therefore this imaging modality is 
currently the closest to the above mentioned desired need to assess different soft tissues and 
pathological processes in vivo. It involves that detailed comprehension of pathophysiology of 
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myocardial infarction is inevitable for the interpretation of cardiac MRI images following 
myocardial infarction. 
1.2.1 Pathophysiology of Myocardial Infarction 
The coronary artery is vulnerable to atherosclerosis, which is the main cause of ischemic heart 
disease. The cause of acute myocardial infarction is usually the thrombotic occlusion of an 
epicardial coronary artery [6]. The duration of myocardial ischemia determines whether an 
episode of vascular occlusion leads to reversible or irreversible myocardial injury. After the 
onset of insufficient myocardial oxygenation, it takes several hours before larger amounts of cell 
death occur and myocardial necrosis can be identified by macroscopic or microscopic post-
mortem examination. Complete necrosis of all myocardial cells within the area at risk requires at 
least 2–4 h or longer depending on the presence of collateral circulation to the ischemic zone, 
persistent or intermittent coronary arterial occlusion, the sensitivity of the myocytes to ischemia, 
pre-conditioning, and/or, finally, individual demand for myocardial oxygen and nutrients [7].  
Within 10 seconds after occlusion of the coronary artery, the myocardium initiates anaerobic 
glycolysis, followed by the accumulation of lactate and other metabolites [8]. Acute myocardial 
infarction begins in the subendocardium within 20–40 minutes after occlusion of the coronary 
artery and spreads toward the subepicardium. This concept of infarct progression has been 
termed the wavefront of myocardial necrosis [9, 10]. In histology level [11], nuclear shrinkage 
and loss, as well as cytoplasmatic eosinophylia are seen initially. Interstitial edema, hemorrhage, 
contraction band necrosis and leukocyte infiltration can be observed within the first 4 days, 
which is called acute inflammatory response. Contraction band necrosis is characterized by 
hypercontracted myofibrils and contraction bands and mitochondrial damage, caused by calcium 
influx into dying cells resulting in arrest of the cells in the contracted state. This phase is 
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followed by granulation tissue formation that manifests itself by penetration of blood capillaries 
and connective tissue from the periphery.  
In terms of clinical therapy it is essential that the diagnosis of an acute coronary syndrome 
should be established quickly and accurately as therapy has to be instigated to limit myocardial 
necrosis [7]. Additional myocardial cell death may occur from reperfusion after prolonged 
ischemia (reperfusion injury) [12]. During ischemia, a large portion of the area at risk undergoes 
biochemical and pathological changes, associated with anoxia but remains potentially viable. At 
reperfusion, the potentially viable cells may reverse the changes occurring during ischemia and 
recover normal function or progress to necrosis. Without intervention, in the first four days, the 
size of the infarct region may expand. Until the third week, muscle fibers are removed (subacute 
infarct) and then replaced by collagen formation in the following weeks (fully mature scar). It is 
followed by a long process of scar maturation and the remodeling of the myocardium, which 
takes several months.   
Reperfusion of ischemic myocardium can be implemented by either iv. fibrinolysis, percutaneous 
coronary intervention (PCI) or coronary artery bypass grafting (CABG). Even after restoration of 
the flow in the occluded coronary artery, expansion of infarction and progression of 
microvascular obstruction may occur [10, 13, 14]. Postischemic reperfusion intensifies the 
development of interstitial or intracellular edema in the injured areas [15-17]. Intramyocardial 
hemorrhage is a common type of reperfusion injury. It is more common in reperfused infarcts (it 
takes about 33-38% of all cases) than in non-reperfused ones. Hemorrhage is disadvantageous 
for the potential recovery of left ventricular function following reperfusion therapy of myocardial 
infarct [18, 19]. Hemorrhage occurs in severely injured areas. It is surrounded usually by non-
hemorrhagic necrotic tissue [20, 21].   
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1.3 Cardiovascular MRI  
Significant advances were necessary to get from the basic principles of NMR to the generation of 
images of the human body. MRI has revolutionized medical imaging for many organ systems. 
Due to the motion of the heart, however, the development of cardiac MRI was slower than that 
of MRI for other organs due to the requirement for faster acquisition techniques. Compared with 
any other body structures, the ever-pumping heart in the respiratory-tided thorax represents the 
most difficult organ to image [22]. With advancements in MRI technology, these obstacles have 
been overcome and cardiac MRI has become a validated tool for imaging the heart. 
1.3.1 Pulse sequences  
Pulse sequences are a pattern of radiofrequency pulses and magnetic gradients that are used to 
produce an image. There are a variety of different pulse sequences that are used in cardiac 
imaging. Not intended to be exhaustive, we are listing the most often used techniques for cardiac 
MRI.  
Spin-echo (SE) sequence is one of the oldest pulse sequences used for imaging [23]. Because of 
the long acquisition time with SE, its faster version, Turbo-spin-echo Sequence (TSE) is used 
recently. The most frequent application of TSE sequences is the T2-weighted edema imaging in 
myocardial infarct. High spatial resolution breathhold T1 Turbo-spin-echo imaging with and 
without fat saturation allows detailed differentiation between myocardium, epicardial fat, 
trabeculae and myocardial fatty infiltration in Arrythmogenic Right Ventricular Cardiomyopathy 
(ARVC) [23].  
Gradient echo (GE) sequences allow significantly shorter acquisition times to be achieved than 
with spin-echo sequence. Its variant, Fiesta provides high blood/myocardium contrast, makes it 
suitable for wall motion analysis and accurate noninvasive determination of different 
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hemodynamical parameters. Inversion Recovery Fast Gradient echo sequences are used to null 
the signal from a desired tissue to accentuate surrounding pathology. A common use of this 
technique is to null the signal from normal myocardium during delayed enhanced (DE) imaging 
(see later). The nulled normal myocardium will be dark in contrast to the enhanced abnormal 
myocardium. IR pulses have a special parameter known as inversion time (TI). When attempting 
to null normal myocardium, one must find the appropriate TI at which the normal myocardium is 
dark. To determine the appropriate TI for an individual, a TI scout series is obtained where each 
image in the series has a progressively larger TI. 
1.3.2 MRI Contrast Agents  
1.3.2.1 Overview 
High spatial resolution MRI is sometimes performed with the use of intravenous contrast agents 
to enhance the signal of pathology or to better visualize the blood pool or vessels.  Despite the 
fact that MR images were initially thought to provide enough endogenous contrast, the utilization 
of exogenous MRI contrast agents (CAs) has increased steadily to reach approximately 40–50% 
of the examinations currently performed [24].  Most MRI contrast agents are Gadolinium 
chelates. Gadolinium ion (Gd3+) complexes (chelates) with a high thermodynamic and kinetic 
stability are required for the use of Gadolinium ion in vivo, giving appropriate biodistribution 
and safety profile [4]. Namely, Gadolinium cannot be used as CA in its Gd3+ ionic form, due to 
its high toxicity and undesirable biodistribution (accumulating in bones, liver or spleen). Gd3+, 
like any other metal ions with one or more unpaired electrons is paramagnetic, and therefore 
possesses a permanent magnetic moment [25]. 
The paramagnetic effect of gadolinium causes a shortening of T1 relaxation time, leading areas 
with gadolinium to be bright on T1-weighted images. The efficiency of MRI contrast agents is 
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denoted by their R1 relaxivity values, which indicates their ability to decrease T1 relaxation 
times of the water protons per mM unit concentration of Gd3+ ion. The concentration of the 
contrast agent in a given tissue depends on the ratio between the uptake and the release of the 
agent. The contrast enhancement is obtained when the concentration of CA in one tissue is 
higher than the concentration in another one. T1-weighted images give positive image contrast, 
as the image signal intensity increases at the tissue site where the CA concentrates is dominated 
by T1 shortening. Contrast agents are used in Cardiac MRI for evaluation of myocardial 
perfusion, delayed enhanced imaging (myocardial infarctions, infiltrative processes, 
myocarditis), differentiation of intracardiac masses (neoplasm vs. thrombus) and to opacify 
blood vessels or left atrium in MR angiography (MRA). 
1.3.2.2 Classification of Contrast Agents for MRI 
 
MRI contrast agents represent a heterogeneous class of diagnostic agents. The most common 
base for classification is their distribution in the body. The distribution of the contrast agent in 
the tissue is determined by its molecular weight, shape and charges [23].    
1.3.2.2.1 Extracellular MRI Contrast Agents 
 
After intravenous injection, extracellular contrast agents quickly and freely distribute to the 
extracellular space [26]. The terminal half-life for blood elimination is about 1.5 hours for all 
these compounds when administered to subjects with normal renal function. The steady-state 
volume of distribution from various pharmacokinetic studies ranges from 210 to 280 mL/kg, 
consistent with an extracellular distribution. These compounds are eliminated almost exclusively 
via the kidneys. 
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Because of their common extracellular distribution, administration of any of these agents yields 
the same diagnostic information. These contrast agents also allow possible diagnosis of certain 
pathological conditions with altered distribution space [22]. The altered distribution space at 
vascular level could be hemangioma and blood-brain barrier breakdown, at interstitial level 
could be regenerative fibrosis, and at cellular membrane integral level could be tissue necrosis or 
infarction, eg. myocardial infarct. Lack of real tissue and/or disease specificity of these contrast 
agents has prompted further research and development of more specific contrast agents. 
1.3.2.2.2 Intravascular MRI Contrast Agents 
 
Intravascular or blood-pool type expression refers to a variety of contrast agents that are confined 
by purpose to the intravascular space and dedicated exclusively to cardiovascular applications. 
The restriction to the intravascular space can be achieved either by reversible binding of the 
contrast agent to plasma albumin (e.g. vasovist [27, 28]) or by the large molecular size of the 
agent which prevents its extravasation through the microvascular wall for some period of time 
(e.g. vistarem [29, 30]). The major advantages of using intravascular agents include a long 
plasma half-life, minimal leakage into the interstitial space, high relaxivities (R1), allowing 
decreased molar dosing. 
1.3.3 MRI of Myocardial Infarct 
1.3.3.1 Viability Assessment with Delayed Enhancement CMR 
Differentiation between viable and infarcted tissue and the quantification of their proportion is 
necessary for clinical decision making. Clearly viable but hibernated myocardium may exhibit 
functional recovery following revascularization of the involved coronary artery by either 
percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) [31]. Patients 
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with decisively nonviable myocardium, on the other hand, must not be jeopardized needlessly 
with the high risk procedures of revascularization [32]. 
The main application of cardiac MRI is the viability assessment following myocardial infarct.  A 
large number of studies have provided considerable information on the value of MRI in 
myocardial infarction. After injection of an extracellular contrast agent (for example, 
Gd(DTPA)), its plasma concentration will reach a maximum value and rapidly decrease due to 
diffusion to the interstitial space and renal washout. Contrast agents diffused to the interstitial 
space will be resorbed into the capillary bed and undergo renal excretion. However, when the 
tissue is damaged, for example due myocardial infarction, the resorption rate of contrast agent 
will be diminished. At 15 to 30 minutes after contrast injection, washout will be complete in 
normal myocardium in contrast to infarcted. This phenomenon is called “delayed enhancement” 
(DE) or “late gadolinium enhancement” (LGE) imaging [33].   
In the last decade, delayed enhancement inversion recovery gradient echo (IR-GRE) MRI with 
standard extracellular contrast agents became the most important and accurate imaging tool for 
assessing either the localization, the transmurality, or the extent, of MIs [34]. DE is also capable 
of differentiating stunned myocardium from necrotic tissue in the acute phase [35], and 
hibernated myocardium from scar tissue in the chronic phase, of a MI [31]. Correspondence 
between location, spatial extent, and 3D shape of the hyperenhanced regions on DE images and 
the irreversibly injured tissue defined by histomorphometry has been demonstrated [35, 36]. 
 
1.3.3.2 Determination of the Age of Myocardial Infarct 
A significant number of heart patients suffer a second heart attack after their first infarction. 
Myocardial reinfarction happens in 7-8% of patients with previous MI [37, 38]. According to 
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recent data [39], the rate of reinfarction is ~ 3% already in the first year in patients with MI 
treated primarily with balloon angioplasty with or without stenting. Differentiation between 
acute and older myocardial infarcts is of great importance in clinical decision-making. There are 
several clinical scenarios where differentiation between acute and older myocardial infarct may 
be crucial. Differentiation between acute and older MIs, however, represents a challenge for 
existing imaging modalities [40]. Wall motion abnormalities detected with either 
Echocardiography, CT, or MRI are not restricted to acute events. In radionuclide imaging, 
radioactive tracers are not taken up by the non-viable myocardial cells regardless of the age of 
the MI.  Therefore, both recent and long-standing MI appears as a fixed defect. Thus, a fully 
reliable method is needed which would determine the age of infarct. 
A significant shortcoming of the Delayed Enhancement-MRI method is, that standard 
extracellular contrast agents used with DE-MRI highlight both the acute and the chronic MI. 
Also, the magnitude of signal intensity enhancement is the same in the territory of a MI in the 
two stages [35, 41]. 
We have developed a family of CAs for MRI diagnosis of ischemic heart disease (IHD) [42-45]. 
Among these, Gd(ABE-DTTA) is optimal for cardiovascular purposes. Gd(ABE-DTTA), which 
is still under investigation, is the Gadolinium complex of N-(2-butyryloxyethyl)-N’-(2-ethyloxy-
ethyl)-N,N’-bis[N”,N”-bis(carboxymethyl)acetamido]-1,2-ethanediamine. Recent results show 
that our method differentiates between acute and older myocardial infarct using myocardial 
delayed-enhancement magnetic resonance imaging by this new contrast agent. 
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1.3.4 Detection of reversible ischemia with Dobutamine stress MRI in patients with PAD 
1.3.4.1 Introduction 
The examination of patients with PAD is often not possible or significantly limited with 
conventional noninvasive cardiac tests because of the followings. Exercise ECG cannot be 
implemented due to the short intermittent claudication distance [46] of the patient. Patients with 
PAD often have chronic obstructive pulmonary disease (COPD) as a smoking related disease 
[47]. Therefore, basic hemodynamic measurements or assessment of wall motion abnormalities 
with transthoracic rest or stress echocardiography is often not possible or limited [48]. 
Dypiridamole or adenosine stress testing could be risky in patients with COPD and 
bronchospasm because of adverse reaction of these stressors [49-51]. To find a diagnostic 
imaging method for the cardiac assessment for these patients could help to identify those who are 
at high risk for undesirable cardiac events. Several noninvasive techniques are available for 
evaluating reversible myocardial ischemia; however, many coronary angiograms yield negative 
results that may be explained by low diagnostic accuracy of most noninvasive tests. Dobutamine 
stress MRI (DSMRI) which has grown to a clinically established test in the last two decades is 
able to identify patients with high risk for cardiac mortality and myocardial infarct [52]. This 
method based on the above detailed reasons enables the noninvasive assessment of severe 
coronary artery disease even in patients with PAD. The role of DSMRI, however, is unknown to 
date in this patient population either from Hungarian or from international scientific literature.  
Our recent results show that DSMRI is feasible with low risk for the cardiology assessment of 
patients with peripheral arterial disease. 
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2 OBJECTIVES AND HYPOTHESES 
 
2.1 Overall Goal of the Thesis Project 
In the present work, the main goal was to develop a new method that differentiates between 
acute and older myocardial infarcts, allowing in vivo infarct age determination by delayed-
enhancement magnetic resonance imaging using a new contrast agent and to prove that 
Dobutamine stress MRI is safe and feasible method for the noninvasive cardiac assessment of 
patients with PAD, yielding identification those who are at high risk for undesirable 
cardiovascular events. 
2.2 The first series of the investigation 
In the first series of our investigations we aim to examine the ability of our method to 
differentiate between acute and 4 week old infarcts in vivo in a subject having both type of 
myocardial infarct. For that specific aim a canine, closed chest, reperfused, double infarct model 
will be used. Two myocardial infarcts will be generated in the animals by occluding the Left 
Anterior Descending (LAD) coronary artery with an angioplasty balloon for 180 min, and four 
weeks later occluding the Left Circumflex (LCx) coronary artery. Using this model, the age of 
the infarct will be determined by its location. Two different contrast agents will be tested. The 
first agent will be a standard extracellular contrast agent, Gadolinium diethlynetriamine penta-
acetic acid, Gd(DTPA). This agent is the most frequently used agent for delayed enhancement 
MRI. The second agent will be Gd(ABE-DTTA), the new, low molecular weight contrast agent. 
Inversion-recovery gradient-echo (IR-GRE) images will be obtained on day 3 and day 4 after 
second myocardial infarct, using Gd(DTPA) and Gd(ABE-DTTA), respectively. 
Triphenyltetrazolium chloride (TTC) histomorphometry will validate the existence and location 
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of infarcts. Hematoxylin-eosin and Masson’s trichrome staining will provide histologic 
evaluation of infarcts. The signal intensity enhancement will be determined in the two different 
age of myocardial infarct. 
Our assumption is that the two contrast agent will exhibit different behavior during Delayed 
Enhancement MRI. We anticipate that Gd(ABE-DTTA) or Gd(DTPA) will highlight the acute 
infarct, whereas the four-week old infarct will be visualized only by Gd(DTPA), but not by 
Gd(ABE-DTTA). 
We hypothesize the followings:  
1. With Gd(ABE-DTTA), the mean signal intensity enhancement (SIE) will be significantly 
higher in the acute infarct than in the four-week old infarct. 
2. With Gd(ABE-DTTA), the mean signal intensity enhancement in the four-week old 
infarct will not differ significantly from that of in healthy myocardium. 
3. Gd(DTPA) will produce similar signal intensity enhancements in acute and four-week 
old infarcts, i.e. the two values will not differ statistically significant. 
4. The signal intensity enhancement in acute or 4 week old myocardial infarct induced by 
Gd(DTPA) will not be statistically different from Gd(ABE-DTTA)-induced SIE in acute 
infarct. 
The four hypotheses together involves that Gd(ABE-DTTA) differentiates between acute and 4 
week-old infarcts, and induces the same SIE in acute infarcts as Gd(DTPA) does. 
 
2.3 The second series of the investigation 
In the second series of our investigations we aim to determine the affinity of Gd(ABE-DTTA) 
during the subacute phase of scar healing, and to compare it to the affinity during the late 
20 
 
subacute phase already studied in the first series of our investigations. To implement that 
comparison, a different MI model and experimental design will be used. For that specific aim a 
canine, closed chest, reperfused, single MI model will be used in a longitudinal study. In this 
series of our investigations a single MI will be generated by occluding for 180 min the Left 
Anterior Descending (LAD) coronary artery with an angioplasty balloon. This single infarct will 
be followed up by the new low molecular weight contrast agent, Gd(ABE-DTTA)-enhanced DE-
MRI. DE-MRI images will be obtained on days 4, 14, and 28 after MI with Gd(ABE-DTTA). In 
addition, control visualization of the infarct by a standard extracellular contrast agent, 
Gd(DTPA) (it is also used in the first series of the investigation) will be carried out on day 27, to 
ascertain that the infarct will be still in place even when the acute-infarct specific agent did not 
highlight it. T2- weighted TSE images will be acquired on day 3, 13 and 27. Triphenyltetrazoli-
um chloride (TTC) histomorphometry will test postmortem (day 28) the existence of infarct. 
Our assumption is that the new contrast agent will exhibit different behavior during Delayed 
Enhancement MRI in the different ages of the infarct scar development. We anticipate that 
infarct affinity of Gd(ABE-DTTA) disappears already in the subacute phase of scar healing,  i.e. 
Gd(ABE-DTTA) will highlight the infarct on day 4, but not on day 14 or on day 28 following 
MI. We also anticipate that the conventional T2-weigted edema imaging highlights the infarcts 
and the segments supplied by the infarct-related artery (“area at risk”) similarly in the acute, 
subacute and late subacute phase, i.e. T2w imaging is not able to distinguish among these 






We hypothesize the followings: 
1. On day 4, the mean signal intensity (SI) of infarcted myocardium in the presence of 
Gd(ABE-DTTA) will significantly differ from that of healthy myocardium, but it will not on 
day 14, nor on day 28.  
2. The mean signal intensity enhancement (SIE) induced by Gd(ABE-DTTA) on day 4 will 
be significantly different from mean SIE on day 14, and from mean SIE on day 28 following 
MI. 
3. The mean SIE values induced by Gd(ABE-DTTA) on day 14 and on day 28 will not 
differ significantly between them. 
4. Gd(DTPA) will highlight the infarct on day 27. 
5. The mean SIE on day 3, 13, or 27 will not vary significantly (P=NS) on the T2-TSE 
images.   
The five hypotheses together involve that Gd(ABE-DTTA) differentiates similarly between acute 
and 2-week-old MI as it does between acute and 4-week old MI, while conventionally used T2-
weighted edema imaging does not have similar properties.  
 
2.4 The third series of the investigation 
In the third series of our investigations we aim to prove that Dobutamine stress MRI is a safe 
and feasible method for the noninvasive cardiac assessment of patients with PAD. For that 
specific aim 21 patients with peripheral artery disease will be studied prospectively with 
dobutamine stress cardiovascular MRI. To attain the 0.85 × (220 – age) target heart rate, the dose 
of Dobutamine will be elevated up to 40 µg/kg/min and supplemented with 0.25 mg/min 
Atropine up to 1 mg if require. The stress will have been terminated before target heart rate will 
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be reached if inducible wall-motion abnormalities appear or angina occurs. Following stress, 
Gd(DTPA) will be given and late enhancement (LE) MRI will be implemented. MRI images will 
be analysed independently by two senior cardiologists experienced in cardiac imaging and 
having European accreditation for CMR. The readers will be blinded to the clinical data of the 
patients. Standardized scoring system (1=normokinetic 2=hypokinetic 3= akinetic 4= dyskinetic) 
and the 17-segment model of the American Heart Association will be applied. The interobserver 
agreement for the assessment of wall motion abnormalities will be calculated. Image quality of 
different anatomical localizations will be graded on a 4-point scale based on the visibility of the 
endocardial border at rest and during stress. Image quality between different anatomical 
localizations will be analyzed. Difference of image quality of four anatomical regions (anterior, 
lateral, inferior, and septal) at rest or during stress will be studied. Symptoms, side effects, and 
adverse events will be recorded. The rate of inducible wall motion abnormalities will be 
determined.  
Our assumption is that different aspects of feasibility and safety will be acceptable in this group 
of patients.  
We hypothesize the followings: 
1. The interobserver agreement for the assessment of wall motion abnormalities will be at 
least good. 
2. Median [interquartile range] image quality score for all anatomical localizations will be at 
least good (3 [3-3]) on the 4-point scale either at rest or during stress. 




4. There will not be statistical difference between image quality of four anatomical regions 
(anterior, lateral, inferior, and septal) at rest or during stress. 
5. The protocol of the study will be completed by a significant number of the patients.  
6. The target heart rate will be attained in a high proportion of the studies.  
7. The side effects could be regarded to be acceptable, and serious adverse events will be 
rare. 
The seven hypotheses together involve that Dobutamine stress MRI is a safe and feasible method 














3 DIFFERENTIATION OF ACUTE AND FOUR-WEEK OLD MYOCARDIAL 
INFARCT WITH GD(ABE-DTTA)-ENHANCED CMR 
3.1 Introduction  
Reinfarction occurs in 7-8% of cardiac patients with previous MI [37, 38].  In a recent meta-
analysis [39], with 6921 patients with MI treated primarily with balloon angioplasty with or 
without stenting, the rate of reinfarction was ~ 3% in the first year. Differentiation between acute 
and older MIs is of great importance in clinical decision-making. Wall motion abnormalities 
detected with echocardiography, computed tomography (CT), or cardiovascular magnetic 
resonance (CMR) are not restricted to acute events. Also, regardless of age of MI, radioactive 
tracers are not taken up by non-viable myocardial cells imaging, and therefore both recent and 
long-standing MI appears as a fixed defect. Not even late enhancement (LE) CMR with standard 
extracellular contrast agents (CA) like Gadolinium-DTPA (Gadolinium-
Diethylenetriaminepentaacetic acid) differentiates by age of infarct [53, 54]. 
We have developed a family of CAs for CMR diagnosis of ischemic heart disease (IHD) [42-45]. 
Among these, Gd(ABE-DTTA) is optimal for cardiovascular purposes. Gd(ABE-DTTA), which 
is still under investigation, is the Gadolinium complex of N-(2-butyryloxyethyl)-N’-(2-ethyloxy-
ethyl)-N,N’-bis[N”,N”-bis(carboxymethyl)acetamido]-1,2-ethanediamine. This low molecular 
weight (764 Dalton) agent’s clearance from the blood has a  kinetics similar to that of blood pool 
contrast agents, although it also displays partly extracellular characteristics [55]. It demonstrates 
high affinity for acute MI [55]. The acutely infarcted tissue takes up Gd(ABE-DTTA) within a 
longer period of time than it does purely extracellular contrast agents. The maximum 
concentration of the agent in the acutely infarcted tissue shows up at 48 hr, although it is not 
significantly different from that which is already achieved at 24 hr, and the contrast remains 
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detectable in the infarct up to 12 days [55]. The agent causes no deleterious physiological effects, 
and a previous study has demonstrated the short- and long term safety of its usage [56].  
Gd(ABE-DTTA) has been successfully used for continuous detection of myocardial ischemia 
during 30 min of left anterior descending coronary artery (LAD) occlusion [57, 58]. The 
suitability of Gd(ABE-DTTA) for accurate quantification of acute MI has also been 
demonstrated [59, 60].  




3.2.1 Gd(ABE-DTTA) sample preparation 
Gd(ABE-DTTA) was synthesized, and samples were prepared, as described by Saab et al. [44]. 
To guarantee consistent quality of agent before administration the in vitro relaxivity was 
measured for every sample [44]. Each animal received Gd(ABE-DTTA) at the dose of 0.05 
mmol/kg, the in vitro relaxation enhancement of which was equivalent to that of Gd-DTPA at its 
conventional dose (0.2 mmol/kg) used for LE-CMR. 
3.2.2 Study design 
Animals were studied with a closed-chest, reperfused, double MI protocol described below. The 
smallest number of animals (n=6) that still achieved statistical significance was used.  MIs were 
generated in the LAD coronary artery territory and four weeks later in that of the left circumflex 
coronary artery (LCx) (Fig. 1.). To avoid a confounding, simultaneous action of the two contrast 
agents, two separate CMR sessions were carried out 3 and 4 days after the generation of the 




Fig. 1 - Timeline of the Study Protocol – Double Infarct Model   
Day 0 - MI generation in LAD-supply area. Day 28 - another MI generation in LCx- supply area. Day 31 (3 days 
after the 2nd MI) - CMR session: obtaining LE images with Gd(DTPA), thereafter administering of Gd(ABE-
DTTA). Day 32 (4 days after the 2nd MI) - CMR session: obtaining LE images with Gd(ABE-DTTA), followed by 
TTC, and histology 
3.2.3 Surgical procedure 
Animal protocol was approved by the University of Alabama at Birmingham IACUC in full 
compliance with the ‘Guidelines for the Care and use for Laboratory Animals’ (NIH). Six male 
hounds (18-20 kg) were used. Twelve hours prior to procedure food was taken away and 325 mg 
Aspirin given. Dogs were anesthetized with a Ketamine (5.0mg/kg) and Diazepam (0.5mg/kg) 
mixture, intubated, and connected to a Hallowell EMC Model 2000 respirator (Pittsfield, MA, 
USA) operated with a tidal volume of 400 ml at a rate of 16 BPM. Anesthesia was maintained by 
continuous Isoflurane (2.5-3 volume %), and repeated Fentanyl (50-100ug I.V. every 30 
minutes), administration. Heart rate and blood oxygen saturation were monitored using a pulse-
oxymeter placed on the animal's tongue. ECG electrodes were placed on the chest to record 
electrophysiological signs of myocardial ischemia and arrhythmias. The left femoral artery was 
separated surgically and an arterial sheath (6-8 French) was inserted. An I.V. line was placed to 
administer infusion and drugs. Heparin (100 IU/kg) was given intravenously to maintain the 
activated clotting time (ACT) above 300 seconds. A properly sized 2-3 mm angioplasty balloon 
was introduced under fluoroscopic guidance into the LAD (1st infarct) or the LCx (2nd infarct) 
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and inflated for 180 minutes to create MI. Thereafter, the balloon was deflated to restore 
coronary circulation. Coronary angiography confirmed the reperfusion after balloon deflation. 
On days 3 and 4 after the second infarction, animals were re-anesthetized as described above and 
CMR studies performed. Animals were then sacrificed, hearts excised and embedded in agar. 
The agar block was cut perpendicular to the long axis with a commercial meat slicer into 5 mm 
sections starting from the apex. 2,3,5-triphenyltetrazolium chloride (TTC) was dissolved in 
physiological saline to obtain  2% TTC solution. Slices were immersed in it at 37◦C for 15 min  
and then rinsed with physiological saline. All TTC-stained slices were photographed with a high 
resolution digital camera.  TTC-stained slices were used to validate the existence and location of 
infarcts. 
3.2.4 Magnetic Resonance Imaging 
A 1.5T GE Signa-Horizon CV/i scanner (Milwaukee, WI, USA) was used. A cardiac phased-
array coil and ECG gating were employed. Breath-hold was performed at end-expiration. A 
180o-prepared, segmented, inversion-recovery fast gradient-echo pulse was used with: Field of 
View (FOV) 30 cm, Echo Time (TE) 3.32 ms, Repetition Time (TR) two cardiac cycles (1100-
1600 ms), slice thickness 10 mm. The Inversion Time (TI) was optimized to null the signal of 
normal myocardium. Conventional cardiac angulation planes were set and short axis slices 
covering the entire left ventricle (LV) obtained (six slices per heart). 
In the first CMR session, a 0.2 mmol/kg Gd(DTPA) (Magnevist, Schering, Kenilworth, NJ) 
bolus was administered intravenously. LE images were acquired 15-20 min thereafter. Gd(ABE-
DTTA) was given intravenously at the end of the first CMR session. In the second CMR session, 




Post mortem tissue samples from the infarct and the peri-infarct regions were examined by 
histopathology. The samples were fixed in 10% formalin, embedded in paraffin, and sectioned at 
5 µm thickness. Hematoxylin-eosin and Masson’s trichrome staining was performed.  
3.2.6 Image analysis 
The existence of both acute and four-week old infarcts was validated and their anatomical 
localization determined by analyzing the TTC images. CMR Dicom images were imported as 
image sequences with the use of ImageJ (Wayne Rasband, NIH). The endo- and epicardial 
contours of the LV muscle were traced manually and this circumscribed area was further 
analyzed. Based on the apicobasal localization and anatomical landmarks (LV and papillary 
muscle shape, and the position of the anterior and posterior interventricular grooves), CMR 
images acquired in the presence of the two different contrast agents, as well as the TTC slices, 
were matched. All CMR slices that contained a MI according to the corresponding TTC slices 
were categorized into four groups by anatomical localization of the infarct to either the four-
week old or to the acute category, and by the contrast agent given. 
To separate the acute and the four-week old infarcts for the analysis, the images of slices 
containing both types of MI were partitioned into two images, each reflecting one half of the 
tomographic slice. The partition was done, with ImageJ, along a straight line starting at the 
posterior interventricular groove (0° on the LV circumference), through the center point of the 
LV slice, ending at the 180° point on the LV circumference in the anterolateral region. Thus four 
groups of images were obtained for analysis: Gd(DTPA)acute, Gd(DTPA)4week, Gd(ABE-
DTTA)acute, Gd(ABE-DTTA)4week, to which two control groups, (Gd(DTPA)normal, Gd(ABE-
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DTTA)normal), i.e. normal myocardium with each of the two agents, have been added, bringing 
the number of data groups for analysis to six. 
To avoid observer bias, instead of manual contouring of the infarct and the healthy myocardial 
regions, a pixel-by-pixel analysis was performed. The pixel-by-pixel SI histogram of every CMR 
image, segmented in the above manner, was generated with ImageJ and these histograms were 
used for further analysis. First, the mean SI ±SD of healthy myocardium was determined by 
exporting the histograms to Origin 7.0 (OriginLab Corporation, Massachusetts, USA), and 
employing Gaussian curve fitting on each using the Levenberg-Marquardt algorithm [61]. In 
agreement with a previous publication [62], pixels with SI above the mean + 6 SD of the normal 
myocardium were regarded as enhanced pixels, i.e. pixels of the infarct. The mean SI of these 
enhanced pixels was calculated from this set of pixels in each image. If no pixels above the 
threshold were found, the mean signal intensity of the infarct was concluded to be equal to that 
of healthy myocardium. The mean SIE in each pixel was computed by [63]: 
SIE=100 x (SIi ─ SIn) / (SIn), 
where SIi and SIn are the mean signal intensity in infarct and normal myocardium, respectively. 
3.2.7 Statistical analysis 
Results are reported as mean ± SD. Statistical analysis was carried out by SigmaStat (version 
2.03; SPSS Inc, Chicago, IL, USA). Two-way repeated measures analysis of variance was used 
to compare the SIE values among the six experimental groups. Normal distribution and equality 
of variances were tested. Although the test of normality failed, due to the equality of variances, 
the equality of group sizes, and the high power of the performed test (0.985 with α=0.05), the 
assumption of the F test in the two-way ANOVA with repeated measures was not violated [64]. 
Since an overall significance  (P<0.05) was established for rejecting the null hypothesis that the 
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six groups are not different, pairwise differences between the groups were assessed by using the 
Holm-Sidak method of adjustment for multiple comparisons. 
3.3 Results  
Both the acute (LCx) and four-week old (LAD) infarcts were visible in Gd(DTPA)-enhanced LE 
images of all six dogs. The existence and localization of recent and four-week old infarct were 
confirmed by TTC. Histologic evaluation confirmed acute infarcts with coagulation necrosis, 
inflammation (mostly mononuclear), and multiple foci of calcification in the 4 days old infarct 
areas (Fig. 2).  
 
Fig. 2 – Double Infarct Histology 
Histologic section of a dog LV 32 days following the first (LAD), and 4 days after second (LCx), MI. (A) Acute 
(LCx) MI with coagulation necrosis, inflammation and multiple foci of calcification (40x, Masson’s trichrome). (B) 
Same area at higher magnification. Dying myocardial fibers (white arrow) associated with inflammatory cells, 
Calcium precipitates (white arrowhead) (100x). (C) Late subacute (LAD) MI in the same heart with granulation 
tissue (white arrowhead) and early collagen deposition, interdigitating (white arrow) with viable myofibers (40x, 
Masson’s trichrome).  
Healing with granulation tissue and early collagen deposition, and small areas of interstitial 
fibrosis adjacent to the late subacute infarct were seen in the four-week old infarct areas. 
Gd(ABE-DTTA) did not induce SIE in the subacute (LAD) infarcts, while the acute (LCx) 
infarcts were clearly visible on LE images of all six animals in the presence of this CA (see 




Fig. 3 - Differentiation between Acute vs. Subacute Myocardial Infarctions 
A: TTC stained photograph of a canine (Dog#1) transversal LV slice 32 days following the first (LAD) and 4 days 
after second (LCx) infarct. White arrows point to the acute infarct located in the posterior and postero-lateral 
segments (LCx-supply area). Subacute infarct (white arrowheads) is seen on the border of the anteroseptal and 
anterior segment (LAD-supply area). B: Corresponding LE CMR image taken in the presence of Gd(DTPA). This 
CA does not differentiate between the acute and the subacute infarcts. C: Same as B, after the endo- and epicardial 
contours of the LV muscle had been traced manually D: Image in C thresholded at normal+6SD intensity. E: Same 
CMR image as in B, taken in the presence of Gd(ABE-DTTA) one day following B. Only the posterior and postero-
lateral segments, i.e. the acute infarct, show LE. The subacute infarct is not highlighted by this agent, thereby 
differentiating between acute and subacute infarcts. F: Same as E, after the endo- and epicardial contours of the LV 
muscle had been traced manually. G: Image F thresholded at normal+6SD intensity. 
H: TTC photograph of another canine (Dog#2) LV slice 32 days following first (LAD) and 4 days after second 
(LCx) infarct. White arrows point to the acute (hemorrhagic) infarct in the posteromedial papillary muscle (LCx-
supply area). Subacute infarct (white arrowheads) is seen predominantly in the anterolateral papillary muscle (LAD-
supply area). I: Corresponding LE image with Gd(DTPA). J: Same as I, after the contours of the LV muscle had 
been traced K: Image J thresholded at normal+6SD L: Same CMR image as in I, taken in the presence of Gd(ABE-






Fig. 4 and 5–Short Axis LE CMR Image Set –Dog#1 and Dog#2 
All base-apex slices of dog#1 and dog#2  (see also Fig. 3). Left column – LE images with Gd(DTPA). Right column 
- LE images with Gd(ABE-DTTA).   
33 
 
Mean ±SD SIE values are shown in Table 1 and Fig. 6. With Gd(ABE-DTTA), the mean SIE in 
the areas with acute infarct was 366 ± 167 %, whereas in areas of four-week old infarcts it was 
only 24 ± 59 %. The difference is statistically significant (P<0.05). The mean SIE in four-week 
old infarct areas with Gd(ABE-DTTA) did not differ significantly from SIE of healthy 
myocardium (P=NS). In contradistinction, Gd(DTPA) produced similar mean SIEs in acute (430 
± 124 %) and four-week old infarcts (400 ± 124 %, P=NS). Furthermore, the mean SIE values of 
neither acute nor four-week old infarcts enhanced with Gd(DTPA) were statistically different 
from mean SIE of acute infarct areas enhanced with Gd(ABE-DTTA). These data show that 
Gd(ABE-DTTA) differentiates between acute and 4 week-old infarcts, and induces 
approximately the same SIE in acute infarcts as Gd(DTPA) does.  
 












*Mean ± SD (n=6) signal intensity enhancement (in percent values) by Gd(ABE-DTTA) and 
Gd(DTPA) in the territory of acute and subacute occlusions   
†P values pertain to pairwise comparisons by the Holm-Sidak method of the different subgroups     
 
  










SIE (%)* 366±166 24±59  431±124 400±124 
P value† vs. normal myocardium P<0.05 NS  P<0.05 P<0.05 
P value vs. Gd(ABE-
DTTA)subacute P<0.05   P<0.05 P<0.05 
P value vs. Gd(ABE-DTTA)acute    NS NS 
P value vs. Gd(DTPA)acute     NS 
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3.4 Discussion  
Gd(ABE-DTTA) was capable of differentiating between acute and four-week old infarcts as no 
LE effect was seen in the latter while one is clearly observable in the former. Acute MIs can be 
seen on the LE-CMR images enhanced with either Gd(DTPA) or Gd(ABE-DTTA). Older MIs 
are visible only by Gd(DTPA). Our general observations show in dogs that the agent’s affinity to 
infarcted myocardial tissue disappears between days 10 and 14 following acute myocardial 
infarction. The question of the detailed kinetics of effect disappearance is currently under 
investigation.   
3.4.1 Magnetic resonance imaging for differentiation between new and longstanding MI 
Saeed et al. [65] have recently published similar observations with an intravascular, high 
molecular weight contrast agent, P792, Vistarem (Guerbet Group, Paris, France). They studied 
one infarct at two different time-points in a single MI model. The intravascular agent produced a 
LE in the acute, 3 day old infarct but not in the later, chronic phase, at 8 weeks, after infarction. 
The authors have also proven the superiority of their method over the T2-weighted (T2w) CMR 
technique (also see below) for the distinction between acute and chronic myocardial infarct.   
Other methods for the differentiation between new and longstanding MIs have also been 
published. In a recent publication Hillenbrand et al. [66] reported a method with the combination 
of Gd(DTPA)-enhanced 1H MR and 23Na MR. Due to granulation tissue infiltrates and collagen 
deposition, the 23Na MR signal intensity in the MI area showed a significant decrease during 
infarct healing. Another approach by Abdel-Aty et al. [40] combined Gd(DTPA)-induced LE 
with T2-weighted (T2w) CMR. The distinction was based on an elevated T2w signal intensity 
due to edema which  is located selectively in the newly infarcted tissue [40]. The specificity of 
this method could be limited by the fact, however, that sometimes, especially in the case of 
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ongoing residual ischemia, sustained postinfarction edema can be detected for up to one year 
after MI [67]. Kim et al. [68] used contrast enhanced steady state free precession (SSFP) CMR 
for the distinction between recent and chronic MIs. The mean signal intensity of acute infarct 
areas was elevated during SSFP CMR, two minutes after Gd(DTPA) administration. Chronic 
infarct regions, however, showed signal intensities similar to that of normal myocardium. The 
exact mechanism of the LE phenomenon is not known to date even for standard extracellular 
agents. Increased volume of distribution, due to sarcolemmal membrane rupture in acute infarct, 
and low grade of cellularity with expanded interstitial collagen matrix of chronic scar tissue, 
have been suggested as potential mechanisms for such agents [35, 36, 53, 54, 69]. 
3.4.2 Histological basis of the CMR observation 
The evolution of MI is a complex pathohistological process [70]. Several hypotheses can be 
brought up to explain the selective accumulation of Gd(ABE-DTTA) into acute MIs. The first is 
linked to the partial intravascular nature of Gd(ABE-DTTA) [55]. Microvascular damage in an 
acute infarct [70] could lead to increased microvascular permeability towards CAs with 
intravascular behavior [71, 72], while the remodeled microvessels in healing infarcts [65, 73] 
would reduce such permeability. Having partial intravascular characteristics [55], the above 
mentioned process could increase the wash-in constant of Gd(ABE-DTTA) in acute infarcts, and 
decrease it in four-week old infarcts. A second hypothesis may be attributable to a possible 
necrosis-avidity of Gd(ABE-DTTA). There may be binding sites for the CA among the different 
elements of acute necrotic tissue such as subcellular compartments (ruptured membrane, cytosol, 
mitochondria), calcium precipitates [70, 74], or ingredients of acute inflammatory reactions, 
persisting selectively in acutely infarcted tissue. Thus the progressive, persistent [55] 
accumulation in acutely infarcted tissue of Gd(ABE-DTTA) may be partly due to its partial 
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lipophilic nature [44], whereby lipids derived from the above mentioned cellular components 
may trap this CA. 
 
Fig. 6 - Comparison of SIE Values.  
Mean (n=6) Signal Intensity Enhancement (%) induced by Gd(ABE-DTTA) or Gd(DTPA) in areas of acute (green 
bars) and subacute infarcts (blue bars). 
3.4.3 Study limitations 
Our study has some limitations. The LE images with the two different CAs were performed on 
two consecutive days. Thus, small differences in selection of the planes of the short-axis images 
between the two CMR sessions cannot be completely excluded. These differences, however, 
would not impair the outcome of our studies. 
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On day 31, Gd(ABE-DTTA) was administered at the end of the first CMR session. It brings up 
the possibility, as Gd(DTPA) (in spite of its short half life time) might not have been fully 
cleared from the body yet, that the two contrast agents could potentially interact with each other. 
There is no chemical basis, however, for the assumption of interaction, and that it could have 
influenced the late enhancement phenomenon in the second CMR session, i.e. 24 hours later. 
Publications [55, 59] already demonstrated the ability of Gd(ABE-DTTA) to detect acute 
infarcts. These publications used a protocol where Gd(ABE-DTTA) was administered alone. 
Gd(ABE-DTTA) needs to be administered 24 hours before CMR imaging, and this introduces an 
inconvenience in a clinical setting. It may not be convenient (the cardiology ward and radiology 
are not necessarily close), nor practical for answering the urgent clinical question in a timely 
fashion. This mode of contrast agent administration, however, is not unknown in the practice of 
nuclear cardiology. For example, there is a  protocol for the assessing of myocardial viability 
with rest redistribution 201Thallium SPECT (Single Photon Emission Computed Tomography), 
where repeated delayed imaging is employed 3-4 h or 24 h following the administration of the 
radiotracer [75].  
The slow clearance of Gd(ABE-DTTA) from the body suggests that the time available for 
undesired physiological effects, such as dissociation of Gd from the chelate, may be considerably 
longer than is the case for agents currently approved for human use. It is noteworthy, however, 
that Gd(ABE-DTTA)’s  short- and long term physiological safety has been reported [56].  
3.5 Conclusions  
In summary, we have shown that LE-CMR with separate administrations of Gd(DTPA) and 
Gd(ABE-DTTA) differentiates between acute and four-week old MIs in a reperfused, double 
infarct, canine model.  
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4 Acute infarct selective MRI contrast agent 
4.1 Introduction 
Differentiation between acute and older MIs is of great importance in clinical decision-making. 
There are several clinical scenarios where differentiation between acute and older myocardial 
infarct may be crucial, such as exclusion of myocardial reinfarction in the presence of an old 
infarct, or localization of the "culprit" vessel in patients with multi-vessel CAD in acute Non-ST-
segment-elevation-MI (NSTEMI) in the presence of an old MI. 
In the last decade, delayed enhancement (DE) inversion recovery gradient echo (IR-GRE) MRI 
with standard extracellular contrast agents became the most important and accurate imaging tool 
for assessing either the localization, the transmurality, or the extent, of MIs [34]. DE is also 
capable of differentiating stunned myocardium from necrotic tissue in the acute phase [35], and 
hibernated myocardium from scar tissue in the chronic phase, of a MI [31]. A significant 
shortcoming of this method is, however, that standard extracellular contrast agents used with 
DE-MRI highlight both acute and chronic MI. Also, the magnitude of signal intensity 
enhancement in the territory of MI in the two stages is similar [35, 41]. 
We have  shown [76, 77] that a low molecular weight MRI contrast agent developed in our 
laboratory, Gd(ABE-DTTA), induces a DE effect in acute (four-day old), but not in late subacute 
(four-week old), MI in a canine, double infarct model. The infarct affinity of Gd(ABE-DTTA), 
however, is not known between days 4 and 28 following MI. The purpose of the current study 
has been the determination of this affinity in the subacute phase of scar healing, and to compare 
it to the already known affinity during the late subacute phase. For the purpose of this 
comparison, a different MI model and experimental design were applied compared to those 
previously used [76, 77]. In the present study a single myocardial infarct was generated and 
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followed longitudinally, and determination of the contrast agent’s affinity was extended to day 
14. This design allowed the comparison of the SIE produced by Gd(ABE-DTTA) on day 4 to 
those on day 14 as well as on day 28.  
Gd(ABE-DTTA) is in investigational phase, and has no deleterious physiological effects [78]. Its 
clearance from the blood has a kinetics similar to that of blood pool contrast agents, although it 
also displays partly extracellular characteristics [55]. It demonstrates high affinity for acute MI 
[55], with slow, distinctive tissue-persistent kinetics. Gd(ABE-DTTA) is taken up into, and is 
washed out from the acutely infarcted tissue slowly, in contradistinction from the kinetics of 
standard extracellular agents’ uptake and wash-out. This CA attains its maximum concentration 
in the acutely infarcted tissue around 48 hr after administration, but a useful contrast is already 
achieved at 24 hr. The contrast remains detectable in the infarct for a few days [55]. Gd(ABE-
DTTA) quantifies the extent of acute MI accurately [59, 60].  
We hypothesized that Gd(ABE-DTTA) differentiates similarly between acute and 2-week-old 
MI as it does between acute and 4-week old MI, ie. the infarct affinity of Gd(ABE-DTTA) 
vanishes already in the subacute phase of scar healing. 
 
4.2 Methods 
4.2.1 Gd(ABE-DTTA) sample preparation and administration 
 
Gd(ABE-DTTA) was synthesized, and samples were prepared, as described by Saab et al. [44].  
The in vitro relaxivity was measured for every sample [44] to guarantee consistent quality of 
agent sample before administration. Gd(ABE-DTTA) was administered  at the dose of 0.05 
mmol/kg 24 h before every Gd(ABE-DTTA)-enhanced DE-MRI session. This dose was four-
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fold lower than the typical dose (0.2 mmol/kg) at which Gd-DTPA had been used for DE-MRI, 
yet induced an in vitro relaxation enhancement equivalent to that of the higher dose Gd-DTPA.  
4.2.2 Study design 
 
Dogs (n=7) were studied in a longitudinal, closed-chest, reperfused, single MI model, as follows. 
MI was generated by occluding for 180 min the LAD coronary artery with an angioplasty 
balloon. Inversion-recovery fast gradient echo (IR-FGE) MRI images were obtained on days 4, 
14, and 28 after MI, and delayed enhancement was generated with Gd(ABE-DTTA). On days 13 
and 27 post MI, the same MRI IR-FGE image sequence was used without contrast agent, to 
demonstrate that the previously administered tissue-persistent CA, Gd(ABE-DTTA), totally 
cleared from the myocardial infarct as judged by comparison to precontrast images. In addition, 
control visualization of the infarct was carried out on day 27 with Gd(DTPA) (standard 
extracellular contrast agent), to ascertain that the infarct was still in place despite the fact that the 
acute-infarct specific agent did not highlight it. To avoid a potential interaction of the two CAs, 
Gd(ABE-DTTA) was administered on day 27 only upon the complete clearing of Gd(DTPA). 
T2-weighted Turbo Spin Echo (T2-TSE) images were acquired on day 3, 13 and 27 before 




Fig. 7 – Experimental design and timeline of events 
 
4.2.3 Surgical procedure 
The animal protocol was approved by the IACUC of our institution in full compliance with the 
‘Guidelines for the Care and use for Laboratory Animals’ (NIH). Seven male hounds (18-20 kg) 
were used. Twelve hours prior to procedure food was taken away and 325 mg Aspirin given. 
Hounds were anesthetized with a Ketamine (5.0mg/kg) and Diazepam (0.5mg/kg) mixture, 
intubated, and connected to a Hallowell EMC Model 2000 respirator (Pittsfield, MA, USA) 
operated with a tidal volume of 400 ml at a rate of 16 BPM. Anesthesia was maintained by 
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continuous flow of Isoflurane (2.5-3 volume %), and repeated Fentanyl (50-100ug I.V. every 30 
minutes) administration. ECG electrodes were placed on the chest to record electrophysiological 
signs of myocardial ischemia and arrhythmias. Heart rate and blood oxygen saturation were 
monitored using a pulse-oxymeter with the probe placed on the animal's tongue. The left femoral 
artery was separated surgically and an arterial sheath (6-8 French) was inserted. An I.V. line was 
placed to administer infusion and drugs. Heparin (100 IU/kg) was given intravenously to 
maintain the activated clotting time (ACT) above 300 seconds. A properly sized 2-3 mm 
angioplasty balloon was introduced into the LAD under fluoroscopic guidance and inflated for 
180 minutes to create MI. Thereafter, the balloon was deflated to restore coronary circulation. 
Fluoroscopic coronary angiography confirmed the onset of reperfusion after balloon deflation. 
On day 3, 4, 13, 14, 27, and 28 following MI, animals were re-anesthetized as described above, 
and MRI studies performed. After the last MRI session, animals were sacrificed, hearts were 
excised and sliced (5 mm thick slices). TTC staining (2%, 37°C) was carried out to validate the 
existence of myocardial infarcts. Both sides of each TTC slice were digitally photographed. 
 
4.2.4 Magnetic Resonance Imaging 
A 1.5T GE Signa-Horizon CV/i scanner (Milwaukee, WI, USA) was used. A cardiac phased-
array coil and ECG gating were employed. Breath-hold was performed using a manual switch on 
the respirator at end-expiration. A 180°-prepared, segmented, inversion-recovery fast gradient-
echo (IR-FGE) pulse sequence was used with: Field of View (FOV) of 30 cm, Echo Time (TE) 
of 3.32 ms, Views per Segment of 16, Shot Length of 114.8 ms, Repetition Time (TR) two 
cardiac cycles (1100-1600 ms), slice thickness of 10 mm, Image Matrix of 256x256, Flip Angle 
of 25°, NEX of 1. The Inversion Time (TI) was optimized to null the signal in normal 
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myocardium. Double inversion-recovery (black-blood) fast-spin-echo images were generated at 
end-diastolic phase of the cardiac cycle with the following parameters: FOV of 30 cm, TE of 60 
ms, Echo Train Length of 16, Shot Length of 140 ms, TR of two cardiac cycles (1100-1600 ms), 
Slice Thickness of 10 mm, Image Matrix of 256x256, Flip Angle of 90°, NEX of 1. 
Conventional cardiac angulation planes were set and short axis slices covering the entire LV 
were obtained (six slices per heart). The scan (breathhold at end-expiration) time per image was 
15-20 s for DE-MRI or for T2w imaging. The total imaging time was around 6 min for both 
sequences.     
4.2.5 Contrast Agent  
In the MRI session on day 13, the IR-FGE sequence was used without CA administration. On 
day 27, a 0.2 mmol/kg Gd(DTPA) (Magnevist, Schering, Kenilworth, NJ) bolus was 
administered intravenously. DE images were acquired with the IR-FGE sequence 15-20 min 
thereafter. In the MRI sessions on days 4, 14, and 28, DE images were similarly obtained, 24h 
after i.v. administration of 0.05 mmol/kg Gd(ABE-DTTA).  
4.2.6 Image analysis 
MRI Dicom images were imported as image sequences with the use of ImageJ. In all images, the 
endo-, and epicardial contours were traced manually. Efforts were taken to avoid including any 
artificially high signal intensity (SI) due to inadequately suppressed slow flow within the left 
ventricular cavity space on T2w images. Large regions of interests, remote from the infarct, were 
selected to measure baseline SI ± SD of the healthy myocardium.  All other analyses were 
automated to eliminate observer bias. In accordance with the literature [62], pixels with SI above 
the mean + 6 SD of the normal myocardium were regarded as “enhanced” pixels. A myocardial 
region was regarded as affected [79] when at least 10 connected pixels of the myocardium 
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revealed enhanced signal intensity. Regions of interest (ROIs) were drawn automatically (by 
ImageJ) around all areas of the affected pixels in every infarct-affected slice, and their mean SI 
was measured. If no 10 connected enhanced pixels were found in any slice of a DE image set, an 
ROI (~100 pixels) was placed in the center of infarcted (but unenhanced) myocardium based on 
TTC staining [80], and the mean SI was measured on the stored image. The mean percent SIE 




SISISIE  100  
where SIi and SIn were the mean signal intensity in infarct and normal myocardium, respectively.  
4.2.7 Statistical analysis 
Statistical analysis was carried out by SigmaStat (Version 2.03; SPSS Inc, Chicago, IL, USA) 
and SPSS (Release 13.0; SPSS Inc, Chicago, IL, USA). Results are reported as mean ± SD. One-
way repeated measures analysis of variance was used to compare mean signal intensity 
enhancement (SIE) of DE images enhanced by Gd(ABE-DTTA) or by the T2 weighting 
sequence on the different days, since these data sets passed both the normality and the equality of 
variances tests. An overall significance (P<0.05) was established for rejecting the null hypothesis 
that the three groups are not different, therefore pairwise differences between the groups were 
assessed by using the Holm-Sidak method of adjustment for multiple comparisons. Two-way 
repeated measures analysis of variance was used to compare the SI values among experimental 
groups (factor 1:  infarct vs. normal, factor 2: age of infarct). Although the test of normality 
failed in this data set, thanks to the equality of variances, the equality of group sizes, and the high 
power of the performed test (0.989 with α=0.05), the assumption of the F test in the two-way 
ANOVA with repeated measures was not violated [64]. An overall significance (P<0.05) was 
established for rejecting the null hypothesis that the six groups are not different. Pairwise 
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differences between the groups were assessed by using the Holm-Sidak method of adjustment for 
multiple comparisons. 
A value of P<0.05 was considered significant in all statistical tests. 
 
4.3 Results  
 
Gd(ABE-DTTA) highlighted the infarct in all cases on day 4, but not at all on day 14 or on day 
28 following MI (see an example shown in Fig. 8). By days 13 and 27 post MI, the previously 
administered Gd(ABE-DTTA) completely cleared from the myocardium, including the infarct 
area. The mean ± SD signal intensity (SI) of infarcted myocardium in the presence of Gd(ABE-
DTTA) significantly differed on day 4 from that of healthy myocardium (45 ± 16.0 vs. 10 ± 5.0, 
P<0.05), but it did not on day 14 (11 ±  9.4 vs. 10 ± 5.7, P=NS), nor on day 28 (7 ± 1.5 vs. 7 ± 
2.4, P=NS) (Fig. 9.). The mean ± SD signal intensity enhancement (SIE) induced by Gd(ABE-
DTTA) was 386±165% on day 4, significantly different from SIE on day 14 (9±20%), and on 
day 28 (12±18%) following MI (P<0.05). The last two mean values did not vary significantly 
(P=NS) between them. Gd(DTPA) highlighted the infarct in all cases on day 27, inducing a SIE 





Fig. 8 - Differentiation Between Acute vs. Subacute Myocardial Infarctions 
DE images taken in the presence of Gd(ABE-DTTA) on days 4, 14, and 28 after MI (panels 1 through 3 from top, 
respectively). Gd(ABE-DTTA) highlights the infarct on day 4 (see arrows), but does not on days 14 and 28. DE 
image set with Gd(DTPA) on day 27 (panel 4 from top). This image set ascertains that infarct is present (see arrows) 
despite the fact that it is not highlighted by Gd(ABE-DTTA) anymore. Corresponding TTC slices (panel 5 from top, 






Fig. 9 - Comparison of signal intensity values at Different Infarct Ages  
Mean (n=7) Signal Intensity values induced by Gd(ABE-DTTA) in areas of infarcts (bright blue bars) vs. healthy 
myocardium (dark blue bars) at different infarct ages. P values pertain to pairwise comparisons by the Holm-Sidak 
method of the six different experimental subgroups.     
 
T2 weighted (T2w) signal enhancement was seen in the segments supplied by the infarct related 
artery (IRA) (Fig. 10). This enhancement appeared not only during the acute but also during the 
subacute and late subacute phase of the MI. The pattern of the enhancement was very similar in 
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these three different phases of scar healing.  The mean ± SD SIE on day 3, 13, or 27 did not 
differ significantly (P=NS) on T2-TSE images (114±41%, 123±41%, and 150±79%, 
respectively). The existence of infarcts was also confirmed by TTC staining. 
 
Fig. 10 - T2w images 
Corresponding T2 weighted black-blood spin-echo images (TE=60 ms) of the same dog on Fig. 3 taken on days 3, 
13, and 27 post MI (panels 1 through 3 from top, respectively).  Note, that T2w signal enhancement can be observed 
in the anterior and anteroseptal segments not only during the acute but also during the subacute and late subacute 
phases of the myocardial infarct. The entire LAD-supply area (infarct related artery) is enhanced (area at risk), and 
not only the infarct- containing slices are involved. The pattern of the T2w-enhancement is quite the same in the 3 
different phases of infarct scar healing.  
 
4.4 Discussion  
It had been shown earlier that Gd(ABE-DTTA) differentiates between acute and 4-week old 
myocardial infarcts (MI) in a canine, double infarct model [76, 77]. This previous model was 
designed to demonstrate the agent’s ability to differentiate between acute and late subacute MIs 
in an animal having both types of myocardial infarct simultaneously. The principal finding of the 
current study is that Gd(ABE-DTTA) has a similar ability already at an earlier age of infarct, i.e. 
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14 days following MI. It shows that the infarct affinity of Gd(ABE-DTTA) has already vanished 
in the subacute phase of scar healing. This study also confirms the agent’s ability to differentiate 
acute and older myocardial infarcts in an experimental study design different from the design in 
the previous study. It is also demonstrated, that T2w imaging highlights the infarcts and the 
segments supplied by the infarct-related artery (“area at risk”) similarly in the acute, subacute 
and late subacute phase, i.e. T2w imaging is not able to distinguish among these different phases 
of the myocardial infarct healing during the time window the study uses while Gd(ABE-DTTA) 
does, using the animal model, phased-array coil, and pulse sequences described above. 
To the best of our knowledge, similar results have not been obtained using any other MRI 
contrast agent or any other MRI method, capable of differentiating new myocardial infarcts from 
existing acute infarcts as early as in the subacute phase, achieving this with high sensitivity and 
specificity. 
Several methods using cardiovascular MRI for differentiation between acute and older 
myocardial infarcts have been published, but none of them showed ability to differentiate an 
acute infarct from a subacute infarct, allowing its use for infarct age differentiation early on. 
An intravascular, high molecular weight contrast agent, P792, Vistarem (Guerbet Group, Paris, 
France) was recently studied by Saeed et al. [65] at two different time-points in a single MI, in a 
porcine model. Vistarem induced hyperenhancement in the acute infarct but not in the later, 
chronic phase of MI. The authors have also demonstrated the superiority of their method over the 
T2-weighted (T2w) MRI technique for differentiation between acute and chronic MI. The 
significant difference from our current study was that Saeed at al. elucidated the affinity to MI of 
the CA in an advanced, chronic phase of scar healing, at 2 months of infarct age.  
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Similarly, Abdel-Aty et al. [40]  compared patients’ MI in the acute vs. chronic phase. They 
combined Gd(DTPA)-induced DE with T2-weighted (T2w) MRI. T2-weighted MRI sequences 
are sensitive to water-bound protons. The distinction was based on an elevated T2w signal 
intensity due to infarct-related edema, which was expected to be present exclusively in the acute 
phase of MI [40].  Abdel-Aty et al. applied their method to compare with an older infarct than 
was investigated in our current study.     
Kim et al. [68] used contrast enhanced steady state free precession (SSFP) MRI for the 
differentiation between acute and chronic (above 6 month old) MIs in patients.  Two minutes 
after Gd(DTPA) administration they observed elevated mean signal intensity in  acute infarct 
areas with SSFP MRI. Chronic infarct regions, however, showed signal intensities similar to that 
of normal myocardium.  
Our results showing that T2w imaging enhances the signal intensity in the territory of myocardial 
infarcts in subacute and late subacute infarcts are in accord  with a previous publication of 
Johnstone at al. [81]. They found that the T2 relaxation time of the infarcted myocardium 
increased markedly at 3 days and remained elevated for 2 months in rabbits.     
A 14 days old infarct is markedly different from a 28 days old infarct from the histological point 
of view. Richard et al. evaluated 14 day old myocardial infarcts [82] in a canine, reperfused 
model which were “characterized by a central core of persistent necrotic myocytes surrounded 
by an irregular rim of inflammatory cells, macrophages, and young scar (granulation tissue) 
composed of fibroblasts, new capillaries, and collagen”. Histology samples taken from four week 
old myocardial infarcts of canines [76, 77], on the other hand, showed a more advanced stage of 
healing, with granulation tissue, collagen deposition, and small areas of interstitial fibrosis 
adjacent to the late subacute infarct. It is clear from these tissue differences that no extrapolations 
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could be made about the affinity of Gd(ABE-DTTA)  to subacute infarct on the basis of results 
obtained in late subacute infarct, and that experimental comparison between the two was 
warranted. It also needs to be noted, from a potential clinical point of view, that MRI distinction 
between an acute and a subacute infarct would be of paramount importance for the in vivo 
validation of a pathological and clinical entity, the myocardial infarct extension. Infarct 
extension is defined clinically as an early in-hospital reinfarction after myocardial infarction, 
appearing in histology as acute foci of contraction band necrosis around a subacute infarct [83]. 
Until now, the in vivo verification of this pathological entity has not been possible with any 
imaging modality due to the lack of capability for differentiation between an acute and a 
subacute infarct. 
The exact mechanism of the DE phenomenon is not known to date even for standard 
extracellular agents. Enlarged distribution volume due to sarcolemmal membrane rupture in 
acute infarcts and low grade of cellularity with expanded interstitial collagen matrix in chronic 
scar tissue have been suggested as potential mechanisms for infarct accumulation of such agents 
[35, 36, 53, 54, 69].  The exact mechanism of delayed enhancement effect induced by Gd(ABE-
DTTA) is not known to date, either. The possible mechanisms [76, 77]  may differ from that 
induced by standard extracellular CAs considering the different behaviour of the two agent types 
in subacute infarcts. 
The differentiation shown by Gd(ABE-DTTA) on the basis of infarct age as early as in the 
subacute phase, indicates that this agent may become a reliable diagnostic tool in several 
important clinical situations, once it is approved for human application. The most important 
potential scenarios would be the following: 
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1. Localization of the "culprit" vessel in patients with multi-vessel CAD in acute NSTEMI in 
the presence of an old MI 
In the course of a non-STEMI in patients with multi-vessel CAD, the determination of the culprit 
vessel could be challenging if the ECG is non-informative. In these cases, DE-MRI with standard 
extracellular contrast agents (eg. Gd(DTPA)) can localize the myocardial infarct (NSTEMI). If 
an older infarct is also present, Gd(DTPA) will highlight both the old and the new infarct. The 
additional use of Gd(ABE-DTTA) could selectively highlight the infarct corresponding with the 
culprit vessel. This could serve as a guide to the interventionalist for PCI.       
 
2 . Detection of the extension of the myocardial infarct in its subacute phase. 
Infarct extension is an event in the course of myocardial infarction [84]  with serious short and 
long term consequences. It is defined clinically as an early in-hospital reinfarction after 
myocardial infarction. The pathologic finding of infarct extension is necrotic and healing 
myocardium with different recent (acute and subacute) ages within the same infarct territory 
[83]. Until now, the in vivo verification of this pathological event was not possible with any 
imaging modality due to the lack of capability for differentiation between an acute and a 
subacute infarct. Gd(ABE-DTTA), however, would be able to distinct between acute and 
subacute myocardial infarcts allowing the in vivo verification of extension of the myocardial 
infarct.   
4.4.1 Study limitations 
Our study has some limitations. Because of its special tissue kinetics properties, it is necessary to 
administer Gd(ABE-DTTA)  ca. 24 hours before MRI imaging., This introduces an 
inconvenience, but not an unprecedented one, in a clinical setting.  
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4.5 Conclusions  
In summary, we have shown that DE-MRI using Gd(ABE-DTTA) differentiates with high 
sensitivity and specificity between acute and 2-week-old (subacute) MI as it does between acute 
and 4-week old (late subacute) MI, in a reperfused, canine, single MI model. The infarct affinity 
of Gd(ABE-DTTA) vanishes as early as the subacute phase of scar healing. 
This feature of Gd(ABE-DTTA) may become a reliable tool in several clinical situations, 
assuming the agent’s approval for human application.  
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5 Dobutamine stress cardiovascular magnetic resonance imaging in patients 
with peripheral artery disease 
5.1 Introduction 
Peripheral arterial disease (PAD) is a significant epidemiological problem by which 3278 
percutane angioplasty (PTA) and 5101 amputations are implemented annually in Hungary [85]. 
Due to the systemic nature of the atherosclerosis and because of the typical existence of 
multiplex lesions, patients with peripheral arterial disease often have coronary heart disease as 
well, therefore the risk of coronary events is high. Most of the patients with PAD dies in 
consequence of his/her coronary artery disease [3]. Also very serious coronary artery disease can 
remain often asymptomatic because of the physical disability of the patient with PAD.  
As it can be seen, the cardiology assessment of patients with PAD would be of great importance 
even if they do not have cardiac symptoms. However, their examination with conventional 
noninvasive cardiac tests is usually not possible or significantly limited because of the 
followings. Exercise ECG cannot be implemented due to the short intermittent claudication 
distance [46] of the patient. Patients with PAD often have chronic obstructive pulmonary disease 
(COPD) as a smoking related disease [47]. Therefore, basic hemodynamic measurements or 
assessment of wall motion abnormalities with transthoracic rest or stress echocardiography is 
often not possible or limited [48]. Dypiridamole or adenosine stress testing could be risky in 
patients with COPD and bronchospasm because of adverse reaction of these stressors [49-51]. 
Dobutamine stress MRI (DSMRI) which has grown to a clinically established test in the last two 
decades is able to identify patients with high risk for cardiac mortality and myocardial infarct 
[52]. This method based on the above detailed reasons enables the noninvasive assessment of 
severe coronary artery disease even in patients with PAD. The role of DSMRI, however, is 
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unknown to date in this patient population either from Hungarian or from international scientific 
literature. The aim of this study was to survey the safety and feasibility of DSMRI for the cardiac 
assessment of patients with PAD.  
5.2 Patients and methods 
5.2.1 Patients 
The protocol of the study was approved by the Institutional Review Board of Flór Ferenc 
Hospital of Pest County and that of the Scientific Biomedical Committee. 21 patients (4 females, 
17 males; mean ± SD age 64 ± 7.7 years) were enrolled after giving written informed consent. 
The patients were treated by the Flór Ferenc Hospital of Pest County because of PAD (ankle-
brachial index 0.54 ± 0.18), and their medical history and current symptoms were negative from 
cardiology point of view. Patients having contraindications for MRI or administration of 
Dobutamine and/or Atropine [86, 87]  were excluded from the study (Table 2).  
Table 2 - Exclusion criteria 
 
Pacemaker non-compatible with MRI 
Cardioverter defibrillator, neurostimulator 
Starr-Edwards prosthetic valve  
Intracranial aneurysm clips 
Ear implants 
Severe dyspnea at rest 
Allergy to Dobutamine 
Significant valvular heart disease 









The main data of the patients can be seen in Table 3. 
 




Patients suspended their β-blocker treatment at least 24 hour before DSMRI. Blood pressure was 
measured by an automatic blood pressure monitor attached to a cuff with a long rubber tube. 
Systolic/diastolic blood pressure and heart rate were measured and documented in the beginning 
and in every 3 minuts of the examination. A catether was inserted into the cubital vein for later 
adminstration of Gadolinium-content MRI contrast agent and Dobutamine infusion (Atropine). 
Resustitation acquipment and defibrillator were installed at the entrance of the MRI scanner 
room. DSMRI was implemented in a group of the patients on a Vision Plus 1.5 T MRI scanner 
(Siemens, Erlangen Germany) (owner: Huniko Ltd., Miskolc, Hungary) in the Flor Ferenc 
Hospital of Pest County. The rest of patients was examined on a Signa Excite 1.5 T scanner 
  
Main characteristics of the patient population  
Sex (female, male) 4/17 
Age, years 64±7,7 
Body mass index, kg/m2  26,4±4,4 
Main clinical data  
Hypertension 17 (80,9%) 
Diabetes mellitus 7 (33,3%) 
Hyperlipoproteinaemia 13 (61,9%) 
Smoking 12 (57,1%) 
Arteriosclerosis in family history 12 (57,1%) 
Ankle/brachial index 0,54±0,18 
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(General Electric Healthcare, Milwaukee, USA) owned by Raditec Ltd. (Budapest, Hungary). A 
six-element cardiac coil was used for signal acquisition. The synchronization of the acquisition 
was performed by triggering on the R wave of ECG lead by MRI compatible chest electrodes. 
The ECG served as a continuous monitor of heart rhythm at the same time. The acquisition was 
implemented in expiratory breath-hold. 
The positioning of the patient in the scanner was followed by definition of cardiac axes using 
localizing images. For that purpose, rapid gradient echo sequence was used for Vision Plus and 
Fiesta sequence was applied for Signa Excite. The three typical planes (4 chamber, 3 chamber, 2 
chamber views) were setup and cine images were acquired. For that purpose, gradient echo 
sequence was used for Vision Plus with these technical parameters: spatial resolution of 1.6 × 1.6 
× 8 mm3, repetition time (TR) of 80 ms, echo time (TE) of 4.8 ms, flip angle of 20°. The breath-
hold time per slice was kept around 15 s. The prospective ECG gating pertaining to the used cine 
gradient echo acquisition sequence necessitated the continuous adjusting of number of phases 
acquired per heart cycle to the wide range of heart rates (50-150/min) during stress protocol. 
Cine MRI on Signa Excite was implemented by Fiesta sequence: spatial resolution of 1.6 × 1.6 × 
8 mm3, TR of 3.57 ms, TE of 1.58 ms, flip angle of 50°. This sequence uses retrospective gating, 
20 phases per heart cycle were setup. Three short axis (basal, midventricular, apical) planes and 
at least one of the long axis planes were selected for further imaging. The cine MRI images 
acquired during every level of the stress protocol were setup in these planes. These planes 
covered the 17 segments of the entire left ventricle according to the recommendation of the 
American Heart Association for standardized myocardial segmentation and nomenclature in 
cardiac imaging [88]. Dobutamine hydrochloride was administered intravenously by a digital 
injector in doses of 10, 20, 30, and 40 µg/kg/min. New or worsened wall motion abnormalities as 
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well as image quality on the acquired cine images were continuously monitored. If segmental 
wall motion abnormalities were detected in rest, the stress was started at dose of 5 µg/kg/min of 
Dobutamine. This enabled to recognize hibernating myocardium hence the motion of the given 
segment improves at this dose of Dobutamine. In case of the lack of other reasons, the 
administration of Dobutamine was terminated if the age predicted target heart rate was reached. 
This was calculated by the formula of (220-age) × 0.85.  If the target heart rate was not attained, 
additional intravenous Atropine boluses were given in 0.25 mg fractions in every 60 seconds up 
to 1 mg.  
During stress, cine images were acquired using the aforementioned MRI sequences. Three short 
axis (basal, midventricular, apical) planes and at least one of the long axis planes were setup, the 
very same planes selected for the imaging in rest. ECG and the symptoms were continuously 
monitored and documented while the blood pressure and heart rate were recorded. Standard 
termination criteria were used [89, 90] (Table 4).   
Table 4 - Termination criteria before the target heart rate reached  
 
 
New or worsening wall motion abnormalities 
Decrease  of systolic blood pressure >40 Hgmm 
Significant (>240/120 mmHg) increase of systolic blood pressure 
Serious chest pain 
Severe dyspnoea 
Impairment of global left ventricular function 
Complex ventricular arrhythmias 
Atrial fibrillation/flutter with high ventricular response 






The stress was followed by rest phase acquiring further cine images. The spontaneous relief of 
symptoms might occur during stress was facilitated by iv. metoprolol (5-10 mg). After 
Dobutamine stress, Gadopentane-dimeglumin (Magnevist, Bayer-Schering Pharma AG, 
Germany) was given. 10-15 min following contrast agent administration, late enhancement 
images were acquired. For that purpose, inversion recovery gradient echo sequence was used 
either for Vision Plus or for Signa Excite with the following parameters: spatial resolution of 1.6 
× 1.6 × 8 mm3, repetition time of 2 cardiac cycles (1100-1600 ms), echo time of 3.4 ms (Vision 
Plus) or 3.67 ms (Signa Excite), flip angle of 20°. The duration of breath holding was around 15 
seconds for every slice.                    
5.2.3 Image analysis 
MRI images were analysed independently by two experienced cardiologists having European 
CMR accreditation who were blinded to the clinical data of the patients. Left ventricular end 
diastolic and end systolic volume, the ejection fraction, and the left ventricular mass were 
determined by Segment v1.8 R1021 software (http://segment.heiberg.se) using the short axis 
slices. Endocardial borders on the end diastolic and end systolic images were contoured 
manually. Wall motion abnormalities  were assessed on the screen in synchronized mode on 
three short axis and one long axis cine images acquired in different phases of the stress protocol 
applying standardized scoring system (1=normokinetic 2=hypokinetic  3= akinetic 4= 
dyskinetic) and the 17-segment model of the American Heart Association [88]. Reversible 
ischemia was defined as new wall-motion abnormality (increase of wall motion score) or bifasic 
response in segments with resting wall-motion abnormalities (increase of wall motion 
abnormality followed by re-decrease) appearing in ≥1 segment. The quality of images was rated 
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on a 4-point scale [91]  based on the visibility of the endocardial border (1=poor or 
nondiagnostic; 2= partially or moderately visible; 3=good visibility; 4=excellently visible).  
5.2.4 Statistical analysis 
Statistical analysis was carried out using 15.0 Version of SPSS for Windows and 5.3 Version of 
SigmaStat for Windows (SPSS Inc., Chicago, USA). The normality of the distribution of 
different statistical variables was analyzed with Kolmogorov-Smirnoff test. Variables are 
reported as mean±SD if they passed the test of normality. Otherwise, they a reported as median 
with 25th and 75th percentiles shown in brackets [quartile]. Interobserver agreement for the 
assessment of wall motion abnormalities was determined by kappa test. Kruskal-Wallis analysis 
of variance for nonparametric variables was used for the analysis of the difference of median 
image quality scores between different anatomical regions. The statistical difference between 
median image quality scores at rest or during stress was evaluated by Wilcoxon signed-rank test. 
P≤0.05 was considered significant.  
5.3 Results 
5.3.1 Study group 
Technical problems occurred rarely during MRI examinations. The setup of the EKG lead must 
have been changed in two patients (9.5%) for correct EKG-gating during stress conditions. 







Table 5 - Hemodynamic data 
 
The administration of Dobutamine must have been terminated before the age-predicted target 
heart rate was attained in one, otherwise symptomless patient (4.8%) because of decrease of 
blood pressure more than 40 mmHg from a previous level. The Dobutamine stress was 
terminated in the other 20 patients (95.2%) when the target heart rate was attained. Also the new 
wall motion abnormalities showed up always when the heart rate was reached. Dose of the 
Dobutamine at termination was 20 µg/kg/min body weight in 4 patients (19.0%), 30 µg/kg/min 
in 8 patients (38.1%), 40 µg/kg/min in 9 patients (42.9%). 2 patients needed additional 1 mg 
Atropine (0.25 mg bolus per minute) administration in order to attain the target heart rate. 11 
patients (52,4%) did not have any symptoms during stress. One patient (4.8%) developed a 
  
Left ventricular function (at rest)  
LVEF, % 71,2±9,3 
LVEDV, ml    123,9±41,2 
LVESV, ml     36,3±19,1 
Heart rate, 1/min  
At rest  75,3±15,7 
At maximal stress 134,5±12,1 
Age predicted target heart rate  132,3±6,5 
Heart rate reached in percent of target heart rate 101,7±8,4 
Systolic blood pressure, mmHg  
At rest     140,9±16,1 
At maximal stress  150,9±27,1 
Diastolic blood pressure, mmHg  
At rest     81,4±5,7 
At maximal stress    83,1±12,5 
Heart rate x blood pressure, mmHg/min  
At rest     10625,4±2555,5 
At maximal stress   20319,8±4049,1 
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typical, but not severe angina pectoris. Mild chest discomfort showed up in four (19.0%), 
tachypnoe in one (4.8%), flush and itch of the skin in one (4.8%), palpitation in two (9.5%) 
studies. Tree patients (14.3%) had a couple of isolated ventricular premature beats. 
Administration of intravenous metoprolol following Dobutamine stress was necessary in five 
(23.8%) cases; four patients (19.0%) received 5 mg, one patient (4.8%) received 10 mg. 
Malignant ventricular rhythm disturbances, hemodynamic instability, serious angina or any other 
severe adverse event did not occur. 5 patients (23.8%) have an inducible wall motion 
abnormality during Dobutamine stress. Late enhancement was detectable in 5 cases (23.8%) of 





 Fig. 11 - DSMRI and LE examinations in a patient 
Basal short axis late enhancement (LE) CMR image can be seen in the top raw. White arrows show a subendocardial 
infarct on the border of inferior and inferoseptal segment. Corresponding cine SSFP images are seen in the 
enddiastolic (ED) (middle raw) and in the endsystolic (ES) phase (bottom raw). From left to right, rest, low dose 
(5µg/kg/min), and maximal (in this case 30 µg/kg/min) Dobutamine stress images are demonstrated, respectively. 
Black arrows show that the myocardium is thinned on the border between inferior and inferoseptal segment, 
according to the sebendocardial infarct. Black arrowheads show that this segment is hypokinetic at rest, hence the 
systolic wall thickening is significantly reduced. Sytolic wall thickening is improved at low dose (gray arrowheads), 
and decreased (white arrowheads) at maximal Dobutamine stress (biphasic response). Coronary angiography 
confirmed the occlusion of the right coronary artery (RCA). The occluded part of the RCA was supplied by 
homocoronary collateral anastomoses minimally. 
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5.3.2 Wall motion abnormalities and image quality 
The interobserver agreement for the assessment of wall motion abnormalities was κ =0,87 
(p<0,0001).  Median image quality score for all anatomical localizations was high (4 [4-4]) on 
the 4-point scale at rest or during stress. The apex (segment 17) has relatively the worth median 
image quality at rest (4 [3-4]), while all other segments have 4 [4-4]. Despite of that, the median 
image quality did not change significantly between different anatomical localizations (p=NS). 
There was no statistical difference (p=NS) between image quality of four anatomical regions 
(anterior, lateral, inferior, and septal) at rest or during stress, either. 
5.4 Discussion 
A number of publications have confirmed that Dobutamine stress MRI became a clinically 
established and generally used method for the noninvasive assessment of reversible myocardial 
ischemia [89, 92-100]. Publication of Nagel et al. [95] have proved that Dobutamine stress MRI 
detects reversible ischemia more precisely than Dobutamine stress echocardiography. The use of 
cardiac MRI versus echocardiography has been shown by the study of Nagel et al. to improve 
sensitivity from 74% to 86% while specificity from 70% to 86%. The superiority of 
cardiovascular MRI could be linked to its better overall image quality which was ranked good or 
very good in 82% while simply 51% of patients’ examination with echocardiography [95]. 
Compared to other noninvasive methods, Dobutamine stress MRI could be useful for the 
assessment of patients suspected for ischemic heart disease [89]. To date, it has not been 
published any original papers concerning the feasibility and safety of Dobutamine stress MRI for 
the cardiac assessment of patients with PAD having high risk for cardiovascular morbidity and 
mortality. Serious adverse event did not occur during this study. It is in accord with other 
publications [89, 93, 94, 101-103] found Dobutamine stress MRI to be safe. Wahl et al. [101] 
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published the rate of occurrence of sustained ventricular tachycardia 0.1% while that of sustained 
ventricular tachycardia 0.4% in a population of 1000 patients. Side effects during stress in 
current study could be regarded to be negligible. A favorable ratio was also attained in the sense 
of age- predicted target heart rate during Dobutamine-atropine stress (95.2%). This ratio could be 
ranked good compared to the 85% experienced by Elhendy et al. [104] during treadmill stress of 
patients suspected for coronary artery disease. This difference could be noticed even more 
favorable if the claudication symptoms of the patient population examined in the current study is 
taken into account. The claudication could have limited significantly the maximal stress level 
attained during treadmill test. 
The high median quality scores of the acquired images, the uniformity of the image quality 
scores of different anatomical regions and that of cine images acquired at rest versus during test 
equally show the feasibility of Dobutamine stress MRI in the studied population of patients. It 
has also been shown in this study that Dobutamine stress MRI provides excellent interobserver 
agreement for the assessment of wall motion abnormalities in patients with PAD which probably 
could be linked to the high image quality of the cine CMR images. Further advantage of the 
Dobutamine stress MRI is that the analysis of wall motion abnormities can be combined with 
other cardiovascular MRI technologies such as the Gadolinium late enhancement imaging of 
myocardial infarct scar. With this method, a relatively high rate (23.8%) of unknown myocardial 
infarct involving different percentage of the myocardial wall was detected. This information 
supplemented with that of response to Dobutamine stress MRI can help in the determination of 
salvageable myocardium if revascularization is to be made [31, 105]. Five patients (23.8%) have 
inducible wall motion abnormalities in study. Landesberg et al. [106]  detected a similar rate of 
occurrence of reversible myocardial ischemia with preoperative Thallium Myocardium 
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Scintigraphy in patients with PAD. Compared to that, other publications [89, 95, 101] reported a 
higher rate (42-51-67%) of inducible wall motion abnormalities in patients with angina pectoris 
and suspected for coronary heart disease. The results of this study show that Dobutamine stress 
MRI for the noninvasive cardiac assessment of patients with PAD safe and feasible method.   
6 Discussion 
 
6.1 Determination of the Age of Myocardial Infarct  
 
Differentiation between acute and older myocardial infarcts is of great importance in clinical 
decision-making. To date, differentiation between acute and older MIs represents a challenge for 
existing imaging modalities [40]. Standard extracellular contrast agents used with DE-MRI 
highlight both the acute and the chronic MI. Also, the magnitude of signal intensity enhancement 
is the same in the territory of a MI in the two stages [35, 41]. 
Our first study have shown that our method differentiates between acute and older myocardial 
infarct in a canine, double infarct model, using myocardial delayed-enhancement magnetic 
resonance imaging by a new MRI contrast agent developed in our laboratory.  Gd(ABE-DTTA) 
was capable of differentiating between acute (four-day old) and late subacute (four-week old) 
infarcts. The first study was designed to demonstrate the agent’s ability to differentiate between 
acute and late subacute MIs in an animal having both types of myocardial infarct simultaneously.  
In our second study, have confirmed that Gd(ABE-DTTA) has a similar ability already at an 
earlier age of infarct, i.e. 14 days following MI. Infarct affinity of Gd(ABE-DTTA) vanishes in 
the subacute phase of scar healing. The agent’s ability has been shown to differentiate acute and 
older myocardial infarcts in an experimental study design different from the design in the first 
study. It has also been demonstrated, that conventionally used T2w imaging highlights the 
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infarcts and the segments supplied by the infarct-related artery (“area at risk”) similarly in the 
acute, subacute and late subacute phase. It involves that T2w imaging is not able to distinguish 
among these different phases of the myocardial infarct healing during the time window the study 
uses while Gd(ABE-DTTA) does. These observations are in accord with a previous publication 
of Johnstone at al. [81]. They found that the T2 relaxation time of the infarcted myocardium 
increased markedly at 3 days and remained elevated for 2 months in rabbits. 
Several methods using cardiovascular MRI for differentiation between acute and older 
myocardial infarcts have been published, but none of them showed ability to differentiate an 
acute infarct from a subacute infarct, allowing its use for infarct age differentiation early on [40, 
65, 68].  
The evolution of MI is a complex, dynamic pathohistological process [70] in which dead 
myocytes are removed and replaced by scar. Various rationales for the ability of Gd(ABE-
DTTA) to selectively accumulate in acute myocardial infarct could be put forth, but they should 
be related to the different phases of the above healing process. 
The first explanation could be linked to the partial intravascular nature [55] of Gd(ABE-DTTA). 
The partial intravascular nature means that in the case of normal microvascular endothelial 
structure, the agent penetrates into the extravascular space to a lesser extent than standard 
extracellular agents do. Microvascular damage in an acute infarct [70] could lead to increased 
microvascular permeability towards CAs with intravascular behavior [71, 72], while the  
remodeled microvessels in healing infarcts [65, 73] would reduce such permeability for an 
intravascular agent. Having partial intravascular characteristics [55], the above mentioned 
increased microvascular permeability in acute stage of the disease could augment locally the 
distribution volume of Gd(ABE-DTTA) in the infarct. This can lead to increased concentrations 
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of the agent in the infarcted tissue, ie. to the generation of  hyperenhancement. The decline of the 
microvascular permeability in two-week old, or older, infarcts may result in diminished volume 
of distribution of this type of CA, and, therefore, to the disappearance of the hyperenhancement.  
The second explanation may be based on a possible necrosis-avidity of Gd(ABE-DTTA). 
Binding sites for the CA may exist among the different elements of acute necrotic tissue such as 
subcellular compartments (ruptured membrane, cytosol, mitochondria), calcium precipitates [70, 
74] or ingredients of acute inflammatory reactions, persisting selectively in acutely infarcted 
tissue. The progressive, persistent [55] accumulation  of Gd(ABE-DTTA)  in acutely infarcted 
tissue may be partly due to its partial lipophilic nature [44], whereby lipids derived from the 
above mentioned cellular components may bind this CA. The existence of these presumed 
binding sides may be confined to the acute phase of myocardial infarct which could lead to 
acute-infarct selectivity of this CA. The two hypotheses are not mutually exclusive, as the 
combination of the two mechanisms could lead to the acute infarct selectivity demonstrated. 
 
6.2 Detection of reversible ischemia with Dobutamine stress MRI in patients with PAD 
 
We have discussed above, that examination of patients with PAD is often not possible or 
significantly limited with conventional noninvasive cardiac tests. A diagnostic imaging method 
for the cardiac assessment for these patients is warranted to identify those who are at high risk 
for undesirable cardiac events. DSMRI is able to identify patients with high risk for cardiac 
mortality and myocardial infarct [52] with high sensitivity and specificity. DSMRI permits the 
noninvasive assessment of severe coronary artery disease even in patients with PAD. Our third 
study has demonstrated that DSMRI is feasible with low risk for the cardiology assessment of 
patients with peripheral arterial disease.  
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The lack of serious adverse events during our third study is in accord with other publications [89, 
93, 94, 101-103] found Dobutamine stress MRI to be safe. A favorable ratio of age-predicted 
target heart rate during Dobutamine-atropine stress (95.2%) was also attained compared to the 
85% experienced by Elhendy et al. [104] during treadmill stress of patients suspected for 
coronary artery disease, especially if the claudication symptoms of the patient population 
examined in the current study is taken into account.  
The high median quality scores of the acquired images, the uniformity of the image quality 
scores of different anatomical regions and that of cine images acquired at rest versus during test 
equally show the feasibility of Dobutamine stress MRI in our third study. It has also been shown 
that Dobutamine stress MRI provides excellent interobserver agreement for the assessment of 
wall motion abnormalities in patients with PAD which probably could be linked to the high 
image quality of the cine CMR images. 23.8% of the patients have inducible wall motion 
abnormalities. Landesberg et al. [106]  detected a similar rate of occurrence of reversible 
myocardial ischemia with preoperative Thallium Myocardium Scintigraphy in patients with 
PAD. Compared to that, other publications [89, 95, 101] reported a higher rate (42-51-67%) of 
inducible wall motion abnormalities in patients with angina pectoris and suspected for coronary 
heart disease. 
6.3 Conclusion   
 
Efforts for the decrease of the incidence and case fatality of myocardial infarction are important 
determinants of the desired decline in coronary disease mortality. The better recognition of 
pathological processes of different tissues following myocardial infarct could contribute to these 
efforts. In many ways, cardiac MRI is capable for the in vivo assessment of the irreversibly 
injured myocardial tissue as well as of the ongoing pathological processes during the healing of 
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myocardial scar following myocardial infarct. The phenomenon of acute infarct selectivity of 
Gd(ABE-DTTA) described by our studies could initiate the research for the recognition of 
unknown aspects of the remodeling process post MI. The described method for the determination 
of the age of myocardial infarct may supply better quality of treatment as well as better outcome 
for patients following myocardial infarct, assuming the approval of the new contrast agent for 
human application.  
Another important aspect for the decline of the mortality of cardiovascular disease could be the 
identification of patients without symptoms but having the highest risk for cardiovascular 
mortality. The cardiology assessment of patients with PAD would be of great importance even if 
they do not have cardiac symptoms. The results of our third study show that Dobutamine stress 
MRI for the noninvasive cardiac assessment of patients with PAD safe and feasible method. 
7 NOVEL FINDINGS 
 
In the first series of our investigations we have proven that Delayed enhancement MRI with 
separate administrations of standard extracellular contrast agent, Gd(DTPA), and a new low 
molecular weight contrast agent, Gd(ABE-DTTA), differentiates between acute and late 
subacute infarct in a reperfused, double infarct, canine model. It has also been shown that 
Gd(ABE-DTTA) induces approximately the same SIE in acute infarcts as Gd(DTPA) does. 
We have four new observations in the study: 
1. In canines, with Gd(ABE-DTTA), the mean signal intensity enhancement (SIE) is 
significantly higher in the acute phase of infarct than in the four-week old infarct in a 
reperfused, double infarct model. 
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2. With Gd(ABE-DTTA), the mean signal intensity enhancement in four-week old infarct 
does not differ significantly from that of in healthy myocardium. 
3. Gd(DTPA) produces similar signal intensity enhancements in acute and four-week old 
infarcts, i.e. the two values does not differ statistically significant. 
4. The signal intensity enhancement in acute or 4 week old myocardial infarct induced by 
Gd(DTPA) is not different statistically from Gd(ABE-DTTA)-induced SIE in acute infarct. 
In the second series of our investigations we have shown Gd(ABE-DTTA) differentiates 
similarly between acute and 2-week-old MI as it does between acute and 4-week old MI using 
DE-MRI in a reperfused, single myocardial infarct, canine model. Thus it is evident that the 
infarct affinity of Gd(ABE-DTTA) disappears already in the subacute phase of scar healing, 
allowing the use of this agent for infarct age differentiation early on, immediately following the 
acute phase. This study confirms the agent’s ability to differentiate acute and older myocardial 
infarcts also in a different experimental study design. Conventional T2w imaging highlights the 
infarcts and the segments supplied by the infarct-related artery (“area at risk”) similarly in the 
acute, subacute and late subacute phase, i.e. we have also demonstrated that T2w imaging is not 
able to distinguish among these different phases of the myocardial infarct healing during the time 
window the study uses while Gd(ABE-DTTA) does, using the animal model, phased-array coil, 
and pulse sequences described above. 
The sensitivity and specificity of the method is high. We have four new observations in the 
study: 
 
1. In canines, on day 4, the mean signal intensity (SI) of infarcted myocardium in the 
presence of Gd(ABE-DTTA) differs significantly from that of healthy myocardium, but it 
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does not on day 14, nor on day 28 following myocardial infarct in a reperfused, single infarct 
model. 
2. The mean signal intensity enhancement (SIE) induced by Gd(ABE-DTTA) on day 4 
differs significantly from mean SIE on day 14, and from mean SIE on day 28 following MI. 
3. The mean SIE values induced by Gd(ABE-DTTA) on day 14 and on day 28 do not differ 
significantly between them. 
4. The mean ± SD SIE on day 3, 13, or 27 do not differ significantly (P=NS) on T2-TSE 
images. 
 
In the third series of our investigations we have shown that Dobutamine stress MRI for the 
noninvasive cardiac assessment of patients with PAD is a safe and feasible method. 
We have seven new observations in the prospective study of 21 patients with peripheral artery 
disease with dobutamine stress cardiovascular MRI: 
 
1. The interobserver agreement for the assessment of wall motion abnormalities is almost 
perfect. 
2. Median [interquartile range] image quality score for all anatomical localizations is 
excellent (4 [4-4]) on the 4-point scale either at rest or during stress. 
3. The median image quality does not change significantly between different anatomical 
localizations (P=NS). 
4. There is no statistical difference between image quality of four anatomical regions 
(anterior, lateral, inferior, and septal) at rest or during stress (P=NS). 
5. The protocol of the study is completed by a significant number of the patients.  
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6. The target heart rate is attained in a high proportion of the studies.  
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